Key facts
- IntelliProve’s last known valuation is $3.3M (Nov 2022).
- It has raised $2.4M; the latest was Seed Round ($1.3M) in Jan 2025.
- Notable investors include Imec.istart, Gilles Mattelin, Jorn Vanysacker, Matthias Geeroms, Jeroen De Wit — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for IntelliProve
- ·The full record, as it builds
Funding rounds
No funding rounds for IntelliProve are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About IntelliProve
Developer of a healthcare platform designed for determining vital health parameters. The company's platform offers artificial intelligence-driven health monitoring technology that measures physiological and mental health parameters without the need for a medical device or wearable and by using a smartphone camera that is based on a combination of novel signal processing and computer vision technology, enabling patients to assess health within seconds.
- Sector
- Healthcare
- HQ
- Ghent, Belgium
- Founded
- 2021
- Employees
- 21
- Website
- intelliprove.com/
- Ownership
- Privately Held (backing)
IntelliProve doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IntelliProve shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IntelliProve in its N-PORT filings yet. We sweep new filings monthly.